PDCD1 and neoplasm: A study in intrahepatic cholangiocarcinoma indicates that a high ALKBH5 (m6A demethylase) expression in tumor cells inhibits m6A modification in the 3′-UTR region of PD-L1 mRNA, increasing the sensitivity to anti-PD-1 immunotherapy (Figure 1).